Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBL-HCV1 with antivirals for Hepatitis C in liver transplant patients
NCT01532908Phase 2Terminated
- Sponsor
- MassBiologics
- Start
- Nov 2012
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MBL-HCV1 in hepatitis C (HCV) (2 arms), sponsored by MassBiologics. Primary endpoint: Number of Subjects With Undetectable HCV RNA at Day 56 Post Liver Transplantation. Started Nov 2012; status: terminated.
02
Drugs
MBL-HCV1
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01532908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532908.